Literature DB >> 15650245

Ignored hallmarks of carcinogenesis: stem cells and cell-cell communication.

James E Trosko1, Chia-Cheng Chang, Brad L Upham, Mei-Hu Tai.   

Abstract

Hanahan and Weinberg (2000, Cell 100: 57-70) listed "hallmarks" of cancer that must be considered in order to understand the underlying determinants of carcinogenesis: (a) self-sufficiency in growth signals; (b) insensitivity to growth-inhibitory (antigrowth) signals; (c) evasion of programmed cell death (apoptosis); (d) limitedless replicative potential; (e) sustained angiogenesis; and (f) tissue invasion and metastasis. While these are important phenotypic markers, important concepts--the role of pluripotent stem cells and gap junctional intercellular communication (GJIC)--must be brought into this analysis of carcinogenesis. Carcinogenesis is a multistage, multimechanism process consisting of a single cell that has been irreversibly blocked from terminal differentiation (the initiation stage). The promotion phase is a potentially reversible or interruptible clonal expansion of the initiated cell by a combination of growth stimulation and inhibition of apoptosis. When the expanded initiated cells accrue sufficient mutations and epigenetic alterations to become growth stimulus independent and resistant to growth inhibitors and apoptosis, to have unlimited replicative potential and invasive and metastatic phenotypes, then the progression phase has been achieved. The hypothesis that integrates these hallmarks is that the stem cell and its early progenitor cell are the target cells for the initiation event. These cells are naturally immortal and become mortal only when they are induced to terminally differentiate and lose their telomerase activity. These two types of initiated cells are suppressed by either secreted negative growth regulators (the stem cells) or GJIC (the early initiated progenitor cells). Promoters inhibit either the secreted growth inhibitor to initiated stem cells or GJIC between the initiated progenitor cells and the normal progenitor cells. When a stable resistance to the secreted negative growth regulator or permanent downregulation of GJIC has occurred, the cell has entered the progression phase. These two new concepts contradict the current paradigm that the first phase of carcinogenesis is the immortalization of a normal cell followed by its neoplastic transformation. Our hypothesis is that the first stage of carcinogenesis must prevent the "mortalization" or terminal differentiation of a naturally immortal cell. Chemoprevention and chemotherapeutic implications suggest that one must induce connexin genes in initiated stem cells and restore GJIC in initiated early progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15650245     DOI: 10.1196/annals.1322.023

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  29 in total

1.  Fractal analysis in a systems biology approach to cancer.

Authors:  M Bizzarri; A Giuliani; A Cucina; F D'Anselmi; A M Soto; C Sonnenschein
Journal:  Semin Cancer Biol       Date:  2011-04-13       Impact factor: 15.707

2.  Carcinogenesis and metastasis now in the third dimension--what's in it for pathologists?

Authors:  Carlos Sonnenschein; Ana M Soto
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

3.  Connexin43 increases the sensitivity of prostate cancer cells to TNFalpha-induced apoptosis.

Authors:  Min Wang; Viviana M Berthoud; Eric C Beyer
Journal:  J Cell Sci       Date:  2007-01-02       Impact factor: 5.285

Review 4.  Liver repopulation and carcinogenesis: two sides of the same coin?

Authors:  Fabio Marongiu; Silvia Doratiotto; Stefania Montisci; Paolo Pani; Ezio Laconi
Journal:  Am J Pathol       Date:  2008-03-05       Impact factor: 4.307

5.  Expression of N-terminal truncated desmoglein 3 (deltaNDg3) in epidermis and its role in keratinocyte differentiation.

Authors:  Jung Suk Lee; Hyun Kyung Yoon; Kyung Cheol Sohn; Seung Ju Back; Sun Ho Kee; Young Joon Seo; Jang Kyu Park; Chang Deok Kim; Jeung Hoon Lee
Journal:  Exp Mol Med       Date:  2009-01-31       Impact factor: 8.718

6.  The linear no-threshold relationship is inconsistent with radiation biologic and experimental data.

Authors:  Maurice Tubiana; Ludwig E Feinendegen; Chichuan Yang; Joseph M Kaminski
Journal:  Radiology       Date:  2009-04       Impact factor: 11.105

Review 7.  The role of connexins in prostate cancer promotion and progression.

Authors:  Jarosław Czyż; Katarzyna Szpak; Zbigniew Madeja
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

Review 8.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

9.  Laminin-111 stimulates proliferation of mouse embryonic stem cells through a reduction of gap junctional intercellular communication via RhoA-mediated Cx43 phosphorylation and dissociation of Cx43/ZO-1/drebrin complex.

Authors:  Han Na Suh; Mi Ok Kim; Ho Jae Han
Journal:  Stem Cells Dev       Date:  2012-01-26       Impact factor: 3.272

Review 10.  Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease.

Authors:  Jay Jagannathan; Jie Li; Nicholas Szerlip; Alexander O Vortmeyer; Russell R Lonser; Edward H Oldfield; Zhengping Zhuang
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.